






**Fig. S1. myomiR expression in male, female, and female ArKO muscles and MyHC expression in regenerating TA.** (A) Expression of miR-1, miR-133b, and miR-133a is not sexually dimorphic in the TA. We measured miRNA levels in male (M) and female (F) TAs. Ns are 7-8 per group. (B) Expression of miR-1, miR-133b, and miR-133a is not different between WT and ArKO female mice in the TA. Ns are 5-6 per group. (C) miR-206 expression is not different between WT and aromatase KO (ArKO) females in the gastrocnemius and plantaris (GP) and the soleus (SOL). Ns are 5-6 per group. (D) Embryonic MyHC and (E) IIX MyHC expression in regenerating male TA at the indicated days post-BaCl<sub>2</sub> injury (dpi). Expression levels relative to the uninjured (PBS-injected) contralateral control TA. Control levels are represented as a dashed line at  $y = 1$ . Ns are: 4 3dpi, 3 7dpi, and 2 14dpi. ANOVA indicated a significant effect from injury (line with ‡;  $p \leq 0.0001$ ). Asterisks indicate post-test results. \*\* =  $p \leq 0.01$ , \*\*\* =  $p \leq 0.001$  vs. control.



**E**


Muscle Consensus: (C/G)N(G/A)(G/A)**CA(C/G)(C/G)TG(C/T)(C/T)N(C/G)**

| E-box # | Mouse                          | Score | Human                          | Score |
|---------|--------------------------------|-------|--------------------------------|-------|
| 1       | *TCAAC <b>CAGCTGCCAG</b> = 7.5 | 7.5   | *TCAAC <b>CAGCTGCCAA</b> = 7.0 | 7.0   |
| 2       | GACG <b>CAGGCG</b> ATTG = 7.0  | 7.0   | GGGG <b>CAGGTG</b> ATGG = 7.5  | 7.5   |
| 3       | *TGAA <b>CAATTC</b> TGTT = 5.5 | 5.5   | ∅                              |       |
| 4       | *TGCT <b>CATCTG</b> GCAG = 5.5 | 5.5   | ∅                              |       |
| 5       | CTGG <b>CAGCTGC</b> AGC = 7.5  | 7.5   | *TGGG <b>CAGCTG</b> CTGC = 7.5 | 7.5   |




**Fig. S2. The miR-206 transcriptional enhancer is dependent on conserved, muscle-specific E-boxes.** (A) A 207-bp region approximately 1 kb upstream of the miR-206 locus contains spikes in conservation corresponding to E-box consensus sites. The line drawing below the image (image from Genome Browser (genome.ucsc.edu); blue histogram illustrates conservation across placental mammals) indicates the location of the E-boxes conforming to the consensus sequence CANNTG, with E-boxes conserved in human, mouse, and rat shown in red and those not conserved in human shown in cyan. The complete mouse sequence cloned for reporter gene analysis is also shown with E-boxes similarly color-coded. (B) Activity of a firefly luciferase reporter gene driven by the 200-bp genomic region increases during differentiation of C2C12 cells. We transfected C2C12 cells with the constructs indicated on the x-axis. We induced differentiation 24 hours post-transfection and measured reporter activity at Day 0 (proliferating myoblasts), Day 1, and Day 4 after differentiation initiation. MyoG serves as a positive control and has the myogenin enhancer driving firefly luciferase. 1-way ANOVA indicated a significant effect from day of differentiation (line with ‡;  $p \leq 0.01$ ). Asterisks indicate post-test results. \*\* =  $p \leq 0.01$  vs. Day 0,  $\psi\psi = p \leq 0.01$  vs. Day 1. (C) The miR-206 200-bp reporter responds to expression of muscle regulatory factors (MRFs) in mouse 10T1/2 fibroblasts. We transfected 10T1/2 cells with the reporters indicated on the x-axis and either empty vector control or overexpression constructs for Flag-tagged MRFs. MyoG and miR-206 200-bp both respond to all 4 MRFs, but the strength of activation in the presence of the various MRFs differs between the reporters. 1-way ANOVA indicated a significant effect from MRF expression (line with ‡;  $p \leq 0.0001$ ). Asterisks indicate post-test results vs Empty Vector. \*\* =  $p \leq 0.01$ ; \*\*\* =  $p \leq 0.001$ . (D) *In vivo* imaging of basal promoter-driven reporter gene expression. Reporter gene activity imaging of minTATA negative control reporter as described and quantified in Fig. 2E. Signal intensity was false colored according to the color bar below. (E) The miR-206 transcriptional enhancer contains 3 muscle-specific conserved E-boxes. We analyzed E-boxes from the mouse 200-bp region (numbered from the 5' to the 3' end of the cloned region) and the orthologous human region for conformation to the longer muscle-specific E-box consensus sequence described by Buskin and Hauschka (Buskin and Hauschka, 1989). The consensus sequence is shown above the table with the core E-box in red text. The scoring rubric is 0 points for divergence, 0.5 points for a degenerate sequence match, and 1 point for an invariant sequence match (8 = highest possible score). Asterisks indicate divergence from the muscle


consensus sequence. Ø indicates that there is no orthologous human CANNTG sequence. **(F)** Only conserved E-boxes contribute to transcriptional activation from the miR-206 enhancer. We mutated E-boxes in the WT miR-206 200-bp construct from CANNTG to CANNTA. We mutated conserved E-boxes 1, 2, and 5 individually while we mutated unconserved E-boxes 3 and 4 together in one construct. Finally, we mutated all 5 E-boxes in the construct labeled E-boxless. We transfected C2C12 cells with each mutant construct as well as the WT and allowed them to differentiate for one day. We normalized firefly luciferase activity to control renilla luciferase activity. 2-way ANOVA indicated significant effects from reporter and day of differentiation (line with ‡ and & p ≤ 0.0001). Asterisks indicate post-test results vs D0. \*\*\* = p ≤ 0.001.



**Figure S3. Muscle mass, myomiR, and linc-MD1 analysis in miR-206 KO vs WT mice.** (A) Gastrocnemius and plantaris (GP) and tibialis anterior (TA) muscle masses are not different between 206KO and WT male mice. We normalized muscle masses to tibia length (TL) in male (M) mice. Ns are: 7 WT GP, 6 206KO GP, 7 WT TA, 5 206KO TA. (B) Soleus (SOL), gastrocnemius and plantaris (GP), and tibialis anterior (TA) muscle masses are not different between 206KO and WT female mice. We normalized muscle masses to tibia length (TL) in female (F) mice. Ns are 5 for WT, 3 for 206KO. (C) MyHC mRNA levels do not change in female 206KO SOL as measured by qPCR. WT levels are represented as a dashed line at  $y = 1$ . N was 5 for WT, 3 for 206KO. (D) miR-206 is undetectable in the 206KO male soleus and there is no compensatory change in miR-1 or miR-133b expression as measured by qPCR. Ns are 6 for both genotypes. \*\*\* =  $p \leq 0.001$  vs. WT. (E) linc-MD1 expression is not different between male 206KO and WT soleus as measured by qPCR. Ns are 7 for WT, 6 for 206KO.




**Figure S4. Isoproterenol treatment induces cardiac pathology.** (A) miR-206 expression is low in the healthy LV. We measured miR-206 expression by qPCR in the male mouse LV and TA and found expression to be over 3 orders of magnitude higher in the TA. Ns are 6 for the LV and 8 for the TA. \*\*\*  $p = 1.11 \times 10^{-9}$  vs. LV. (B) Heart rate significantly increased after 7 days treatment with both  $30 \text{ mg kg}^{-1}$  and  $45 \text{ mg kg}^{-1}$  isoproterenol. We measured heart rate in all animals before (solid bars) and after (patterned bars) treatment. \*\* =  $p \leq 0.01$ ; \*\*\* =  $p \leq 0.001$  vs. pre-treatment. (C) Left ventricle (LV) mass is higher in both groups of isoproterenol-treated animals compared to vehicle controls. We measured LV mass and normalized to tibia length (TL). ANOVA indicated a significant treatment effect (line with ‡). \*\*\* =  $p \leq 0.001$  vs. vehicle. (D) Gene expression of  $\beta$ -MyHC, ANF, and BNP in the LVs of isoproterenol-treated mice as measured by qPCR. ANOVA indicated a significant treatment effect (line with ‡). Asterisks indicate post-test results. \* =  $p \leq 0.05$ ; \*\* =  $p \leq 0.01$  vs. vehicle. Ns are 6 for vehicle control and 8 for both  $30 \text{ mg kg}^{-1}$  and  $45 \text{ mg kg}^{-1}$  for all measurements.



**Figure S5. LV mass and M-mode echocardiography measurements.** (A) Left ventricle (LV) mass is not different between 206KO females and WT. We measured LV mass and normalized to tibia length (TL) in female (F) mice. N was 5 for WT and 3 for 206KO. (B) Heart rate was the same between miR-206 KO and WT males and females. Ns were 4 for WT male (M), 5 for 206KO M, 5 for WT female (F), and 4 for 206KO F. (C) (D) M-mode echocardiographic measurements revealed no changes in LV dimensions in female (F) 206KO mice compared to WT. LV anterior wall at systole = LVAW (s), LV posterior wall at systole = LVPW (s), LV interior diameter at systole = LVID (s). Ns are 5 for WT and 4 for 206KO. (E) M-mode echocardiographic calculations revealed no changes in LV function in female (F) 206KO mice compared to WT. LV volume at systole = LV Vol (s), ejection fraction = EF, and fractional shortening = FS. Ns are 5 for WT and 4 for 206KO.





**Figure S6. RNA analysis in left ventricles from male miR-206 KO vs WT mice. (A)** myomiR expression as measured by qPCR. There is no difference in expression of miRs -133b, -1, -208a, or -208b. Ns are 4-6 per group. **(B)** Expression of mRNA corresponding to cardiac stress markers. Acta1 was significantly up-regulated while Mstn was significantly down-regulated. WT levels are represented as a dashed line at  $y = 1$ . Ns are 5-7 per group. \* =  $p \leq 0.05$  206KO vs WT. **(C)** Expression of miRNA cardiac stress markers. WT levels are represented as a dashed line at  $y = 1$ . Ns are 7 for WT and 6 for 206KO.

### Luciferase constructs

miR-206 enhancer SP GGGGTACCTTAATTTTCCCCATCCAGGGTG  
miR-206 enhancer ASP CCAATGCATTGCAGCTGCCAGATGAGCAT

### Mutagenic primers

E-box 1 SP CTGAATGGCTCAACAGCTACCAGTGTCCATTCATC  
E-box 1 ASP GATGAATGGACACTGGTAGCTGTTGAGCCATTCAG  
E-box 2 SP GATTGTGACGCAGGTAATTGGCCACGAGCAGC  
E-box 2 ASP GCTGCTCGTGGCCAATTACCTGCGTCACAATC  
E-box 5 SP GGAATGCTCATCTGGCAGCTACAATGCAGAGGG  
E-box 5 ASP CCCTCTGCATTGTAGCTGCCAGATGAGCATTCC  
E-boxes 3 4 SP CCACAATGAACAATTATGTTGGAATGCTCATCTAGCAGCTGC  
E-boxes 3 4 ASP GCAGCTGCTAGATGAGCATTCCAACATAATTGTTTCATTGTGG

### qPCR

pri-miR-206 TCTGCGTGACAAGTGCCTCG  
TTCTCTGGGTGGAGCCATCG  
 $\beta$ -MyHC TTCCTTACTTGCTACCCTC  
CTTCTCAGACTTCCGCAG  
MyHC IIA ATTTCCCAGCTGCACCTTCT  
AAGACAGATGTTTTGGCATCAA  
MyHC IIX GGTCGAAGTTGCATCCCTAA  
GCTTGTTCTGAGCCTCGATT  
 $\alpha$ -MyHC ACATTCTTCAGGATTCTCTG  
CTCCTTGTTCATCAGGCAC  
Embryonic MyHC GGTCCCATACGTCCACAACCT  
TGCAGCTATGCCAAACACTT  
Mef2c TCTGCCCTCAGTCAGTTGG  
CGTGGTGTGTTGTGGGTATC  
Serca2a GCTCAAGTTTGTGGCAATACTG  
TGCAGAGGGCTGGTAGATG  
Pln GTTGTGCCCTTTTTCTACAC  
AGAGAGAGCAGATTTGTGG  
Mb TGGCCATGGACAGGAAGT  
GGTCCTCTGAGCCCTTCATA  
Tnni1 TCCACAACACCAGAGAGATCAAGG  
GCATGGCATCGGCTGAGACACG  
Tnni2 GAGATGAGGAGAAGCGCAAC  
CGCTATCTGGAGCATCACAC  
Six1 ACCGGAGGCAAAGAGACC  
GGAGAGAGTTGATTCTGCTTGTT  
Eya1 GGGTCTTTAGACAGTTTCTCAGGT  
TGGGTATGATCTGTTGGAAGG  
linc-MYH GTGCAGCCAGAACAAGACAG

|          |   |
|----------|---|
| BNP      | CAAGATGGGAGGCTCTCAA<br>AAGGTGCTGTCCCAGATG<br>TTGGTCCTTCAAGAGCTGTC |
| ANF      | CCAGGCCATATTGGAGCAA<br>GAAGCTGTTGCAGCCTAGTC                       |
| Acta1    | CGACATCAGGAAGGACCTGTATGCC<br>AGCCTCGTCGTACTIONCTGCTTGG            |
| Gapdh    | AGGTCGGTGTGAACGGATTTG<br>TGTAGACCATGTAGTTGAGGTCA                  |
| Gata4    | CCCTACCCAGCCTACATGG<br>ACATATCGAGATTGGGGTGTCT                     |
| Nkx2.5   | CAAGTGCTCTCCTGCTTTCC<br>CTTTGTCCAGCTCCACTGC                       |
| mCip1.4  | AGCTCCCTGATTGCTTGTGT<br>TGGAAGGTGGTGTCTTGT                        |
| Colla1   | AATGGCACGGCTGTGTGCGA<br>AACGGGTCCCCTTGGGCCTT                      |
| Mstn     | GGAAGTATCGATCAGTACG<br>CGCTTGCATTAGAAAGTCAG                       |
| 18S      | GCCGCTAGAGGTGAAATTCTTG<br>CTTTCGCTCTGGTCCGTCTT                    |
| linc-MD1 | GCAAGAAAACACAGAGGAGG<br>GTGAAGTCCTTGGAGTTTGAG                     |

### Genotyping primers

|                          |  |
|--------------------------|--|
| 206KO Primer 1 WT SP     | AAATCTCTAGTGGCCTTTGGGGGAGCC                    |
| 206 KO Primer 3 KO SP    | GCTCTATGGCTTCTGAGGCGGAAAGAACC                  |
| 206KO Primer 2           |  |
| Common ASP               | GCATATTCTCTGGGTGGAGCCATCGG                     |
| ArKO Primer 1            | CGTGGGCAGGTGATCAGTTTACCATGTCCTAATCTTCAC        |
| ArKO Primer 2 WT         | TCTTCTGAGGCCAAATAGCGCAAGATGTTC                 |
| ArKO Primer 3 KO         | CTGCTAAAGCGCATGCTCCAGACTGCCTTG                 |
| <i>mdx4cv</i> WT SP      | GATACGCTGCTTTAATGCCTTTAAGAACAGCTGCAGAACAGGAGAC |
| <i>mdx4cv</i> Mutant SP  | CGGCCAGAACAGCTGCAGAACAGGAGAT                   |
| <i>mdx4cv</i> Common ASP | GCGCGGCTTGCCTCTGACCTGTCCTAT                    |

**Table S1. Primer sequences.** Primers for cloning the miR-206 enhancer, mutagenizing the E-boxes in the miR-206 enhancer, qPCR analysis, and genotyping mice are presented 5' → 3'.

**References:**

**Buskin, J. N. and Hauschka, S. D.** (1989). Identification of a myocyte nuclear factor that binds to the muscle-specific enhancer of the mouse muscle creatine kinase gene. *Mol. Cell. Biol.* **9**, 2627–2640.